Investigational drug · Phase 2
INN imapextide
Also called: MBX 1416
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Postbariatric Hypoglycemia.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "INN imapextide"
First trial start
2025
Aug 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INN imapextide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postbariatric Hypoglycemia
Largest trials
Live from ClinicalTrials.gov: studies naming "INN imapextide" as an intervention, largest first.
MBX BiosciencesIndustry
NCT07029412 · 20 participants · Start Aug 26, 2025 · Primary completion Apr 18, 2026
Drug: MBX 1416 (INN imapextide) · For: Postbariatric Hypoglycemia
Sites: Aurora, Colorado; Morehead City, North Carolina; Knoxville, Tennessee · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Postbariatric Hypoglycemia
- MizagliflozinPhase 21 trial
Vogenx, Inc. · Postbariatric Hypoglycemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.